HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC
NCT06335927
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
45
Enrollment
OTHER
Sponsor class
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
DRUG:
HAIC-GEMOX+Cadonilimab+Regorafenib
Sponsor
Fudan University